Stifel Reiterates Kinnate Biopharma (KNTE) at Buy, Optimistic That KIN-287 Can Improve Efficacy
Tweet Send to a Friend
Stifel analyst Ben Burnett reiterated a Buy rating and $35.00 price target on Kinnate Biopharma (NASDAQ: KNTE), following a recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
